Government funding for uterine cancer research lags behind rising incidence Authors: Rachel P Mojdehbakhsh, Ryan J Spencer, Natalia Gontarczyk Uczkowski, Amy L Godecker Published: 2026 ABSTRACT Highlights•Uterine cancer incidence is rising but federal research funding remains limited.•PRCRP funding for uterine cancer began only in 2021 despite high incidence.•Analysis reveals inequity in DOD cancer funding relative to disease burden.•Findings highlight need for greater investment in uterine cancer research.Keywords: Endometrial cancer, Uterine cancer, Research funding, Department of defense Background Uterine cancer is both the most common gynecologic malignancy as well as the deadliest with over 64,000 new cases estimated in 2024 and over 13,00 deaths (Sherman et al., 2025; Siegel et al., 2024). Additionally, the incidence of uterine cancer continues to rise by 1.4% annually (SEER*Explorer Application [WWW Document], n.d). Continued research into uterine cancer is crucial to both understanding and stopping this increase in incidence and mortality. There are two main funding mechanisms for cancer research through the United States government. The biggest is the National Cancer Institute. Of the dedicated funding areas in 2023, uterine cancer received $15 M of the $7B annual budget, 0.2% ((2023) NCI Budget Fact Book - Research Funding - NCI [WWW Document], n.d). The second largest funding source for cancer research is through the Department of Defense through the Congressionally Directed Medical Research Program (CDMRP), which has a $1.5B annual budget for cancer research funding. Uterine cancer does not have dedicated funding under the CDMRP. To receive funding through the CDMRP with no dedicated funding, grant applications are submitted through the Peer Reviewed Cancer Research Program (PRCRP), some of which are funded after the thorough review process. Despite the PRCRP's existence since 2009, uterine cancer research grants have only received funding since 2021. We aimed to investigate funding patterns and monetary awards uterine cancer research has received through the PRCRP and compare these values to other funded cancers by incidence of disease. Methods To gather funding information from the PRCRP, a thorough review was done of the CDMRP website, where records of grants funded as well as the total budgets for the PRCRP had to be manually abstracted from archives. On the CDMRP website, every topic funded by the PRCRP was recorded for every year the PRCRP has existed, since 2009. PRCRP grants were manually searched for every fiscal year using the terms “uterine” or “endometrial” in the abstract and the abstracts were manually reviewed. For each year, the number of grants and value of each grant were recorded. For the topics funded by the PRCRP, the SEER database was used to gather the incidence of each cancer type. For comparison, the highest incidence cancer funded by the PRCRP, colorectal cancer, and the lowest, mesothelioma, were compared to endometrial cancer with respect to funding. Results The CDMRP received $1.5B in 2023. Under the CDMRP, the Peer Reviewed Cancer Research Program can fund accepted grant proposals from a pool of 130 M. In 2023, uterine cancer research was granted $6M through this program, 0.4% of the total CDMRP budget and 1.6% of the PRCRP budget. Since its creation in 2009, the PRCRP has funded a total of 33 different areas of cancer research, with 18 areas included in 2024. Uterine cancer was added in 2021 and has been funded for 4 years. For comparison, we examined the cancer with the highest and the lowest incidence that was funded through the PRCRP. The cancer with the highest incidence receiving PRCRP funding is colorectal cancer at 37.5 per 100,000 people in 2021. The cancer with the lowest incidence is mesothelioma at 0.7 per 100,000 people in 2021. Endometrial cancer has the second highest incidence at 29.4 per 100,000 people in 2021. Colorectal cancer, has been funded the longest at 15 years and has received a total of ∼$60 million through the PRCRP during that time. Mesothelioma, has been funded for almost as long at 14 years and has received a total of ∼$25 million. Uterine cancer, has only been funded for 4 years and has received only ∼$14 million. Aside from the high incidence alone, uterine cancer has seen a 15% increase in incidence from 2009 to 2021. This is contrasted with colorectal cancer, which has seen a 15% decrease (Fig. 1). Discussion Uterine cancer is the fourth most common cancer affecting women in the US. Despite the rising incidence of uterine cancer in the US, the Department of Defense CDMRP does not award dedicated funding for uterine cancer research. Only recently has uterine cancer been added to the PRCRP funded areas. This is important discrepancy to note because DOD resources benefit a significant number of women including more than just active military members. There are approximately 400,000 women serving in the US military. Of the people with spouses in the military, 92% of these spouses are women, which totals about 1 M people. Additionally, there are approximately 2 M women veterans in the US today. This means that about 3 M women could be directly impacted by DOD funded research let alone the millions indirectly affected in the general US population. Though women may not make up the majority of the population served by the DOD, it should be noted that there has been longstanding dedicated funding for breast cancer through the CDMRP without the need to go through the rigorous PRCRP process. This suggests that the inequity does not lie in the population size served through the DOD, but the disease site. Overall, there appears to be a proportionate inequity in government funding for uterine cancer when considering the rising incidence of this disease. In the 2025 fiscal year, CDMRP funding has been cut by 57% to 650 M. The PRCRP budget has been protected at 130 M (U.S. House Misses Critical Opportunity to Boost Cancer Research and Prevention Funding; Future Progress in Jeopardy | American Cancer Society Cancer Action Network [WWW Document], n.d). Specific funding of endometrial cancer through the PRCRP has not yet been examined or published to our knowledge and remains an inconsistently utilized and perhaps underutilized source of funding for endometrial cancer for individual researchers applying for government grants. Another measure of the relationship between funding and disease morbidity is the disability-adjusted life years (DALY) score. A study looking into the inequities of NIH cancer funding published in 2025 demonstrated that among others, uterine cancer received less than 150% of the expected funding when considering disease burden and public interest (Berglas et al., 2025). When we take into consideration the largest funder of cancer research, the NIH and NCI, endometrial cancer still receives among the lowest federal funding, which remains true when considering the incidence and mortality of the disease. When funding-to-lethality scores were calculated for gynecologic cancers as well as 15 other cancer sites, uterine cancer was found to rank 14th receiving $57,000 per person-years of life lost compared to the top ranked cancer prostate, which received $1,821,000 (Spencer et al., 2018). In hypothesizing why certain cancers receive more government funding than others, national support and support within government organizations is most likely one factor. Diseases such as breast cancer and mesothelioma have large and long-standing foundations and advocacy initiatives that have sustained research funding. Endometrial cancer has not historically had the same presence. More attention is being given to endometrial cancer in the last few years as its incidence has been increasing as well as its lethality. In June 2024, the Ovarian Cancer Research Alliance and other national advocates petitioned congress for a dedicated CDMRP funding program with $10 M of support. This petition was not successful (SGO Advocates Needed to Pursue Expanded Endometrial Cancer Research at the Department of Defense | Society of Gynecologic Oncology [WWW Document], n.d). Campaigns such as the “Spot Her.” launched in 2021 are relatively new and need more support from the general public and physicians to become more impactful. A campaign backed by a pharmaceutical company can reach the public, but may have limited impact without its backing of national organizations like the Foundation for Women’s Cancer and the GOG Foundation, which can involve providers and more directly disseminate resources to patients and more importantly their yet unaffected community members (Take the Spot Her pledge and learn about endometrial cancer [WWW Document], n.d.). As awareness of the disparity in endometrial cancer research funding increases, other advocacy initiatives more directly related to the cause have become more visible. There is a 2026 petition to support the creation of a dedicated funding program through the CDMRP for endometrial cancer with $10 M in initial appropriations for Fiscal Year 2027. The National Defense Authorization Act for Fiscal Year 2026 authorized the creation of this program, but its implementation depends on the advocacy and voices of those it effects. All US citizens, as constituents of the House and Senate members who serve on the Defense Appropriations Subcommittee, are able to voice their support of this unprecedented new source of research funding for endometrial cancer that would help close the large gap in funding that currently exists. During the preparation of this work the author(s) used OpenEvidence in order to conduct a literature review for the purposes of the discussion. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication. CRediT authorship contribution statement Rachel P. Mojdehbakhsh: Writing – review & editing, Writing – original draft, Methodology, Data curation, Conceptualization. Ryan J. Spencer: Writing – review & editing, Supervision, Conceptualization. Natalia Gontarczyk Uczkowski: Formal analysis. Amy L. Godecker: Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Contributor Information Rachel P. Mojdehbakhsh, Email: rmojdehbakhsh@uwhealth.org. Ryan J. Spencer, Email: rjspencer2@wisc.edu. Natalia Gontarczyk Uczkowski, Email: godecker@wisc.edu. Amy L. Godecker, Email: gontarczykuc@wisc.edu, cgodecker@wisc.edu, godecker@wisc.edu. References